



Justification Document for the Selection of a CoRAP Substance

Substance Name (public name): 3-methylbutan-1-ol
EC Number: 204-633-5
CAS Number: 123-51-3

Authority: Bureau for Chemical Substances,
Poland

Date: 22/03/2016

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

CONTENTS

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
1.2	Similar substances/grouping possibilities	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3.1	Classification	5
3.1.1	Harmonised Classification in Annex VI of the CLP	5
3.1.2	Self classification	5
3.1.3	Proposal for Harmonised Classification in Annex VI of the CLP	6
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	7
4.1	Tonnage and registration status	7
4.2	Overview of uses	7
5.	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE	8
5.1.	Legal basis for the proposal	8
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)	8
5.3	Initial grounds for concern to be clarified under Substance Evaluation	8
5.4	Preliminary indication of information that may need to be requested to clarify the concern	9
5.5	Potential follow-up and link to risk management	10

1 IDENTITY OF THE SUBSTANCE


1.1 Other identifiers of the substance

Table: Other Substance identifiers

EC name (public):	3-methylbutan-1-ol
IUPAC name (public):	3-methylbutan-1-ol
Index number in Annex VI of the CLP Regulation:	-
Molecular formula:	C ₅ H ₁₂ O
Molecular weight or molecular weight range:	88.1482
Synonyms:	

Type of substance Mono-constituent Multi-constituent UVCB

Structural formula:



1.2 Similar substances/grouping possibilities

Eight structural isomers with molecular formula C₅H₁₂O and all alcohols are known to belong to the group of primary amyl alcohols.

The registrant has also proposed to use data generated on primary amyl acetate.

2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA	<input type="checkbox"/> Risk Management Option Analysis (RMOA)	
REACH Processes	Evaluation	<input type="checkbox"/> Compliance check, Final decision
		<input type="checkbox"/> Testing proposal
		<input type="checkbox"/> CoRAP and Substance Evaluation
	Authorisation	<input type="checkbox"/> Candidate List
		<input type="checkbox"/> Annex XIV
	Restriction	<input type="checkbox"/> Annex XVII
Harmonised C&L	<input type="checkbox"/> Annex VI (CLP) (see section 3.1)	
Processes under other EU legislation	<input type="checkbox"/> Plant Protection Products Regulation Regulation (EC) No 1107/2009	
	<input type="checkbox"/> Biocidal Product Regulation Regulation (EU) 528/2012 and amendments	
Previous legislation	<input type="checkbox"/> Dangerous substances Directive Directive 67/548/EEC (NONS)	
	<input type="checkbox"/> Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)	
(UNEP) Stockholm convention (POPs Protocol)	<input type="checkbox"/> Assessment	
	<input type="checkbox"/> In relevant Annex	
Other processes / EU legislation	<input type="checkbox"/> Other (provide further details below)	

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)¹

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

Table: Harmonised classification

Index No	International Chemical Identification	EC No	CAS No	Classification		Spec. Conc. Limits, M-factors	Notes
				Hazard Class and Category Code(s)	Hazard statement code(s)		
-	-	-	-	-	-	-	-

3.1.2 Self classification

In the registration:

International Chemical Identification	EC No	CAS No	Classification		Spec. Conc. Limits, M-factors	Notes
			Hazard Class and Category Code(s)	Hazard statement code(s)		
3-methylbutan-1-ol	204-633-5	123-51-3	Flam. Liquid 3	H226: Flammable liquid and vapour.		
			Acute Tox. 4	H332: Harmful if inhaled.		
			Skin Irrit. 2	H315: Causes skin irritation.		
			Eye Irrit. 2A	H319: Causes serious eye irritation.		
			STOT Single Exp. 3 Affected organs: respiratory tract Route of exposure: Inhalation	H335: May cause respiratory irritation.		
EUH066	Repeated exposure may cause skin dryness or cracking.					

- Additional notified classification and labelling according to CLP criteria (beside of self classification of registrant). Taken from:

¹ The ECHA dissemination site was accessed 20.03.2016.

<http://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/cl-inventory/view-notification-summary/24439>:

Muta. 2, H341

Carc. 2, H351

Acute Tox. 4 H302

Eye Irrit. 2 H318

STOT SE 3 H336

Eye Irrit. 2A H319

Skin Irrit. 2 H314

STOT SE 1 H370

Flam. Liq. 4 H226

Eye Dam. 1 H318

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

Not applicable

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES²

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site		
<input checked="" type="checkbox"/> Full registration(s) (Art. 10)	<input type="checkbox"/> Intermediate registration(s) (Art. 17 and/or 18)	
Tonnage band (as per dissemination site)		
<input type="checkbox"/> 1 - 10 tpa	<input type="checkbox"/> 10 - 100 tpa	<input type="checkbox"/> 100 - 1000 tpa
<input type="checkbox"/> 1000 - 10,000 tpa	<input type="checkbox"/> 10,000 - 100,000 tpa	<input type="checkbox"/> 100,000 - 1,000,000 tpa
<input type="checkbox"/> 1,000,000 - 10,000,000 tpa	<input type="checkbox"/> 10,000,000 - 100,000,000 tpa	<input type="checkbox"/> > 100,000,000 tpa
<input checked="" type="checkbox"/> 100+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa)		<input type="checkbox"/> Confidential
There are three registrations.		

4.2 Overview of uses

Table: Uses

Part 1:

<input checked="" type="checkbox"/> Manufacture	<input checked="" type="checkbox"/> Formulation	<input checked="" type="checkbox"/> Industrial use	<input checked="" type="checkbox"/> Professional use	<input checked="" type="checkbox"/> Consumer use	<input type="checkbox"/> Article service life	<input type="checkbox"/> Closed system
---	---	--	--	--	---	--

Part 2:

	Use(s)
Uses as intermediate	Use as Process Chemical
Formulation	Formulation & (re)packing of substances and mixtures, distribution of the substance
Uses at industrial sites	Use in Coatings, Use in Cleaning Agents, Lubricants, Use as binders and release agents, Use in laboratories, Polymer processing
Uses by professional workers	Use in Coatings, Use in Cleaning Agents, Lubricants, Use as binders and release agents, Use in laboratories, Polymer processing
Consumer Uses	Use in Coatings, Use in Cleaning Agents, Lubricants, Personal Care Products
Article service life	-

² The ECHA dissemination site was accessed 20.03.2016.

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE

5.1. Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)
- Article 45(5) (Member State priority)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

- Fulfils criteria as CMR/ Suspected CMR
- Fulfils criteria as Sensitiser/ Suspected sensitiser
- Fulfils criteria as potential endocrine disruptor
- Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
- Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
- Fulfils exposure criteria
- Fulfils MS's (national) priorities

5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns		
CMR <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	Suspected CMR ³ <input checked="" type="checkbox"/> C <input type="checkbox"/> M <input checked="" type="checkbox"/> R	<input type="checkbox"/> Potential endocrine disruptor
<input type="checkbox"/> Sensitiser	<input checked="" type="checkbox"/> Suspected Sensitiser ³	
<input type="checkbox"/> PBT/vPvB	<input type="checkbox"/> Suspected PBT/vPvB ³	<input type="checkbox"/> Other (please specify below)
Exposure/risk based concerns		
<input type="checkbox"/> Wide dispersive use	<input checked="" type="checkbox"/> Consumer use	<input type="checkbox"/> Exposure of sensitive populations
<input type="checkbox"/> Exposure of environment	<input checked="" type="checkbox"/> Exposure of workers	<input type="checkbox"/> Cumulative exposure

³ CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)

Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

<input type="checkbox"/> High RCR	<input type="checkbox"/> High (aggregated) tonnage	<input type="checkbox"/> Other (please specify below)
-----------------------------------	--	---

Suspected sensitiser:

3-methylbutan-1-ol is not classified for skin sensitisation. There are no studies on skin sensitisation available for 3-methylbutan-1-ol. Registrant presented only outcome from the studies performed on structural analog reaction mass of 2-methylbutyl acetate and pentyl acetate. Presented study outcomes for the skin sensitising endpoint (guinea pig maximization test) give conflicting results (negative and ambiguous). Additionally ambiguous results for other structural analogs (primary amyl alcohols) are available.

The registrant declares that no information regarding the respiratory sensitisation properties is available. Taking into account that substance is classified as Acute toxicity (inhaled) and STOT SE 3 (respiratory system) it would be good to obtain more data on sensitisation by inhalation. Data provided in dossier on exposure related observations in humans is not sufficient.

Within the SEV process it should be further evaluated whether the substance might have sensitising properties to the respiratory tract and skin.

Suspected CMR:

Registered substance activates DART (DART profiler in the QSAR Toolbox) alerts for developmental/reproductive toxicity (known precedent reproductive and developmental toxic potential) as implemented in the QSAR Toolbox v3.3. After running a chemical through the decision tree, the results indicated that the chemical of interest is associated with chemical structures known to have DART.

The carcinogenicity of 3-methylbutan-1-ol was evaluated in a studies (disregarded by registrant) which were described in two publications (Gibel et al. 1974, 1975). Postmortal examination after the average life time of 527 days included blood analysis as well as histopathological analysis of the organs, spinal segments and femurs. As result, severe chronic-toxic effects were reported, as liver cirrhosis, myocard necrosis and effects on pancreas and haematopoietic organs as well as tumours distributed over a variety of different organs. There are no additional experimental studies on registered substance, the effects seen in the carcinogenicity test raise concern that the substance is a carcinogen, which needs to be clarified.

Exposure/risk based concerns:

The identified uses in the registration data indicate potential dermal and inhalation exposure to both workers and consumers. Further assessment of the exposure assessment and risk characterisation is required in order to confirm that risks are adequately controlled.

5.4 Preliminary indication of information that may need to be requested to clarify the concern

<input checked="" type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on physico-chemical properties
<input type="checkbox"/> Information on fate and behaviour	<input checked="" type="checkbox"/> Information on exposure
<input type="checkbox"/> Information on ecotoxicological properties	<input checked="" type="checkbox"/> Information on uses
<input type="checkbox"/> Information ED potential	<input checked="" type="checkbox"/> Other (provide further details below)

Depending upon the outcomes of the evaluation.

5.5 Potential follow-up and link to risk management

<input type="checkbox"/> Harmonised C&L	<input type="checkbox"/> Restriction	<input type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details)
---	--------------------------------------	--	--

Harmonised C&L might follow , further action and risk management measures will depend upon the outcome of the evaluation.